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Objective: The study aimed to analyze the risk factors and long-term outcomes associated with coronary artery
aneurysms (CAAs) after successful percutaneous coronary intervention (PCI) and drug-eluting stent (DES)
implantation in patients with CTOs.
Background: There are sporadic data available on post-procedure CAAs after transcatheter revascularization for
CTOs.
Methods and results: A total of 141 patients with 149 CTOs who underwent successful CTO-PCI and DES implan-
tation with angiographic follow-up from 2004 to 2010 were included. Patients were divided into CAA group and
non-CAA group according to the presence of CAAs in the follow-up angiography. The independent predictors and
major adverse cardiac events (MACEs) including cardiac death, myocardial infarction (MI) and target-vessel
revascularization (TVR) were compared between two groups. The incidence of CAAs was 11.4% (17/149) after
index procedure. Multivariate analysis showed that age (OR: 0.925, CI 0.873–0.980, P = 0.008), ostial occlusion
(OR: 6.715, CI 1.473–30.610, P= 0.014), the parallelwire technique (OR: 6.167, CI 1.709–22.259, P= 0.005) and
DES length (OR: 1.030, CI 1.002–1.058, P= 0.036)were the independent predictors of CAAs after successful CTO-
PCI and DES implantation. MACEs were similar between two groups (adjusted hazard ratio 0.670; 95% CI 0.160–
2.808; P = 0.584) during the 5-year follow-up.
Conclusions: The independent predictors of CAAs after successful CTO-PCI andDES implantation are age, ostial oc-
clusion, the parallel wire technique and DES length. CAAs after index procedure are not frequently associated
with adverse clinical events under dual antiplatelet therapy. Further large clinical studies are warranted to ex-
plore the clinical implications of patients with this distinct new entity.
© 2014 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).ovascular Diseases, Zhongshan
64041990 2745; fax: +86 21
is an open access article under the C1. Introduction
Approximate one third of the patients with signiﬁcant coronary
artery disease on angiography have at least one chronic total occlusion
(CTO) [1,2]. Over the last decade, remarkable progress has been
achieved in the percutaneous management of coronary artery disease.
However, recanalization for CTOs of native coronary arteries is still
regarded as the “last frontier” of percutaneous coronary intervention
(PCI) due to its high rates of procedural complications and failure [3].C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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76% [4–6]. With improved operator experience, dedicated devices and
procedural techniques, the success rates have steadily increased in the
past few years. In some experienced center, the procedural success
rate can reach roughly 90% [7]. In spite of these improvements, many
problems such as acute complications, restenosis and coronary artery
aneurysms (CAAs) continue to present a challenge.
CAA is an abnormal dilatation (≥1.5-fold) of part of the coronary
artery and often found coincidentally on coronary angiography. There
are limited published data focused on CAA formation following PCI
supported by drug eluting stent (DES) which is postulated to be associ-
ated with hypersensitivity reactions toward the stent [8,9]. As we all
know, CTO-PCI has a higher probability of using longer stents and
exposing the subintimal structure to the stent, or even stenting
subintimally. However, not any retrospective or prospective study
was designed to focus on the status and outcomes of CAAs after successful
CTO-PCI and DES implantation. Therefore, we designed the current study
to investigate the independent predictors and clinical outcomes for CAAs
which developed after successful CTO-PCI and DES implantation.
2. Methods
2.1. Study population
We reviewed the catheterization database and medical records
at the Shanghai Institute of Cardiovascular Diseases, Zhongshan
Hospital of FudanUniversity and identiﬁed 697 patientswith successful
recanalization of CTOs in the native coronary arteries who presented
from 2004 to 2010. All patients in the current study received follow-
up angiography in the same catheterization center and were divided
into CAA group and non-CAA group according to the detection of
CAAs. Patients with CTOs were excluded when any of the following
was encountered: (1) Procedural failure to open the CTOs; (2) PCI
without DES implantation; (3) Previous attempted percutaneous
transluminal coronary angioplasty (PTCA) to the target CTO; (4) In-
stent restenotic occlusions (Mehran IV pattern restenosis); (5) CAAs
observed in any vessel before PCI; (6) Lack of angiographic follow-up
in our center; (7) Re-PCI to the target CTO vessel before detection of a
CAA in the CAA group; and (8) Duration of angiographic follow-up
b6 months in the non-CAA group. A retrospective chart review was
performed to collect the clinical variables, history and catheterization
information.
The angiographic follow-up duration of the CAA group was deﬁned
as the duration from the 1st successful CTO-PCI to the 1st diagnosis of
CAA. The angiographic follow-up duration of the non-CAA group was
deﬁned as the duration from the 1st successful CTO-PCI to the ﬁnal
recorded angiography unless re-PCI for the target vessel. The long-
term clinical follow-up duration of patients in both groups was deﬁned
as the time from the 1st successful CTO-PCI to July 31, 2013.
All the CTO-PCI procedures were performed by 10 different opera-
tors from our center. All of the operators achieved more than 200 PCI
per year. The regulatory board of the Zhongshan Hospital afﬁliated to
Fudan University approved this study. All the patients gave written in-
formed consent before all the procedure.
2.2. Procedures and medications
All the percutaneous revascularizations of CTOs were performed
according to the current standard guidelines. All patients were
prescribed medicine prior to interventions, with administration of
300mgaspirin and300mgclopidogrel as pretreatment. After operation,
all patients were advised tomaintain their life-long aspirin therapy, and
at least a 12-month clopidogrel prescription.
Intravascular ultrasound (IVUS) was performed using iLAB (Boston
Scientiﬁc, USA). After the intracoronary administration of nitroglycerin
(0.2 mg), the ultrasound catheter (2.5 F Atlantis SR, 40-MHz, BostonScientiﬁc Corporation, USA) was advanced distally to the left anterior
descending artery, the left circumﬂex or the right coronary artery
along the 0.014″ guidewire and was pulled back to the aortocoronary
ostium using motorized transducer pullback at the speed of 0.5 mm/s.
Continuous ultrasound images were obtained and recorded on CDs.
The IVUS data were analyzed by two specially experienced cardiologists
and one experienced technician.
2.3. Angiographic deﬁnitions
CTO is deﬁned as thrombolysis inmyocardial infarction (TIMI) grade
0 ﬂow and the duration of coronary occlusion ≥3 months [3]. In the
absence of serial angiograms, the duration of coronary occlusion is
instead estimated from available clinical information related to the
event that caused the occlusion (eg, acuteMI or sudden change in angina
pattern with ECG changes consistent with the location of the occlusion)
[3]. Angiographic successwas deﬁned as a restoration of TIMI ﬂowgrade
3 in the target vessel after DES implantation and a residual stenosis b10%
by visual estimation.
CAA is typically deﬁned as a dilatation in the diameter of a coronary
artery segment to more than 1.5-fold the normal size by visual estima-
tion [10], and this CAA was closely related to the underlying DES or its
edges, and the localized dilation was absent immediately after the
procedure.
The angiographic indices examined were the location of the CTO,
CAA, diffuse disease proximal to the occlusion (at least one stenosis
of N50% proximal to the occlusion) [11], side branch at the occlusion,
vessel tortuosity (the presence of at least one bend of N45° proximal
to the occlusion) [11], calcium at the site of the occlusion (radio-opacity
present before contrast injection), ostial occlusion (occlusion within
3 mm of the ostium), stump morphology (a blunt or tail-like stump)
and grades of bridging collaterals (0 = none; 1 = ﬁlling of side
branches of the artery to be dilated via collateral channels without
visualization of the epicardial segment; 2 = partial ﬁlling of the
epicardial segment via collateral channels; and 3 = complete ﬁlling
of the epicardial segment of the artery being dilated via collateral
channels) [12]. Angiographic restenosis was deﬁned as a ≥50%
diameter stenosis within the target lesion.
All the ﬁlms were reviewed by two qualiﬁed interventional doctors.
If there was any ambiguity in the reports or ﬁlms, the ﬁlms were
reviewed independently by three well-qualiﬁed interventional doctors.
2.4. Study endpoints
The major adverse cardiac events (MACEs), including cardiac death,
myocardial infarction (MI), and target-vessel revascularization (TVR),
were recorded. MI was deﬁned as elevation of the cardiac troponin
with at least one value above the 99th percentile of the upper reference
limit and with at least one of the following: (1) symptoms of ischemia,
(2) new or presumably new signiﬁcant ST–T changes or new LBBB,
(3) development of pathological Q waves in the ECG, (4) imaging
evidence of new loss of viable myocardium, or new regional wall
motion abnormality, and (5) identiﬁcation of an intracoronary thrombus
by angiography or autopsy [13]. TVR was deﬁned as emergency or
elective coronary artery bypass graft or repeat PCI in the target vessel.
2.5. Statistical analysis
The data were expressed as the mean ± SD for the continuous
variables, and as frequencies for the categorical variables. The
comparison of continuous variables was performed by the independent
Student's t-test or the Mann–Whitney U test as appropriate. Statistical
analysis of the categorical variables was performed using the Pearson
chi-square or Fisher's exact test as appropriate.
Themultivariate logistic regressionmodel (the variables in Tables 1,
2 and 3 with P b 0.1 were entered into the analysis, except for the
Table 1
Baseline clinical characteristics.
Clinical characteristics All patients
(n = 141)
Patients with CAA
(n = 16)
Patients without CAA
(n = 125)
P value
Gender, male 119 (84.4) 15 (93.8) 104 (83.2) 0.467
Age, years 60.35 ± 11.28 51.44 ± 11.84 61.49 ± 10.73 0.001
Angina status
Asymptom 3 (2.1) 0 (0) 3 (2.4) 0.600
Stable 59 (41.8) 5 (31.3) 54 (43.2)
Unstable 79 (56.0) 11 (68.8) 68 (54.4)
Smoking 63 (44.7) 6 (37.5) 57 (45.6) 0.539
Hypertension 101 (71.6) 14 (87.5) 87 (69.6) 0.237
Diabetes 37 (26.2) 2 (12.5) 35 (28.0) 0.238
Prior MI 41 (29.1) 5 (31.3) 36 (28.8) 0.779
Data are presented as mean ± SD or n (%). CAA indicates coronary artery aneurysm; MI, myocardial infarction.
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used to identify the independent predictors of CAAs after successful
CTO-PCI and DES implantation. The Cox proportional-hazards model
was used to test whether CAA was an independent predictor of clinical
outcomes or not. P values were two-tailed, and P b 0.05 was considered
statistically signiﬁcant. The datawere analyzedwith SPSS v.20.0 statistical
software (SPSS, version 20.0, Inc., Chicago, IL, USA).3. Results
Between 2004 and 2010, among 697 patients with successful
recanalization of CTOs in the native coronary arteries, a total of
141 patients with 149 CTOs met the inclusion criteria (Fig. 1). In
the follow-up angiography, CAAs were observed in 17 (11.4%)
lesions of the left anterior descending artery (LAD), left circumﬂex
artery (LCX) and right coronary artery (RCA), respectively (Figs. 2,
3 & 4). Most of the CAAs (13, 76.5%) in the current study were ﬁrst
detected b1 year after the 1st successful procedure. The shortest
duration to detect a CAA was 34 days (Fig. 2) which showed no
morphological change of the CAA after approximately 7 years
(Supplement Fig. 1).Table 2
Angiographic characteristics.
Angiographic characteristics All lesions
(n = 149)
Angiographic follow-up duration, months 17.21 ± 14.67
IRA 41 (27.5)
No. of diseased vessels
1 20 (13.4)
2 50 (33.6)
3 79 (53.0)
Location of CTO
LAD 58 (38.9)
LCX 27 (18.1)
RCA 64 (43.0)
Diffuse disease proximal to occlusion 38 (25.5)
Side branch at occlusion 33 (22.1)
Vessel tortuosity 27 (18.1)
Calciﬁcation 25 (16.8)
Ostial occlusion 17 (11.4)
Stump
No stump 7 (4.7)
Blunt stump 54 (36.2)
Tail-like stump 88 (59.1)
Collateral circulation (grade)
0 6 (4.0)
1 10 (6.7)
2 42 (28.2)
3 91 (61.1)
Data are presented asmean ± SD or n (%). CAA indicates coronary artery aneurysm; IRA, infarc
circumﬂex artery; RCA, right coronary artery.3.1. Baseline characteristics
The baseline clinical characteristics of the patients were represented
in Table 1. The mean age of our cohort was 60.4 ± 11.3 years, 84.4%
were men, 71.6% had hypertension, 26.2% had diabetes and 29.1% had
prior MI. A signiﬁcant difference of the age (51.4 ± 11.8 versus
61.5 ± 10.7 years, P = 0.001) was shown between the CAA group
and non-CAA group. While, there were no signiﬁcant differences in
the other baseline clinical characteristics between the two groups.3.2. Angiographic and procedural characteristics
Table 2 summarized the angiographic characteristics of all the
lesions. The angiographic follow-up duration ranged from 1.1 to
48.5 months in the CAA group and 6.0 to 70.6 months in the non-CAA
group. The difference of angiographic follow-up duration between the
two groups was signiﬁcant (P = 0.012) due to the different design.
53.0% occurred with triple-vessel disease, left circumﬂex arteries
(18.1%) were the infrequent CTO location and ostial occlusion
accounted for 11.4% (17/149) of the overall lesions. Most of CTO's
morphological characteristics which were acknowledged to beCAA group
(n = 17)
Non-CAA group
(n = 132)
P value
11.04 ± 11.28 18.00 ± 14.90 0.012
5 (29.4) 36 (27.3) 1.000
1 (5.9) 19 (14.4) 0.590
5 (29.4) 45 (34.1)
11 (64.7) 68 (51.5)
5 (29.4) 53 (40.2) 0.152
1 (5.9) 26 (19.7)
11 (64.7) 53 (40.2)
3 (17.6) 35 (26.5) 0.562
4 (23.5) 29 (22.0) 1.000
4 (23.5) 23 (17.4) 0.513
1 (5.9) 24 (18.2) 0.308
5 (29.4) 12 (9.1) 0.028
1 (5.9) 6 (4.5) 0.745
5 (29.4) 49 (37.1)
11 (64.7) 77 (58.3)
0 (0) 6 (4.5) 0.958
1 (5.9) 9 (6.8)
4 (23.5) 38 (28.8)
12 (70.6) 79 (59.8)
t-related artery; CTO, chronic total occlusion; LAD, left anterior descending artery; LCX, left
Table 3
Procedural characteristics.
Procedural characteristics All lesions
(n = 149)
CAA group
(n = 17)
Non-CAA group
(n = 132)
P value
Microcatheter 35 (23.5) 7 (41.2) 28 (21.2) 0.124
Number of guidewire 1.88 ± 0.85 2.12 ± 0.86 1.85 ± 0.85 0.222
Maximal stiffness of guidewire tip
b3 g 22 (14.8) 1 (5.9) 21 (15.9) 0.340
3–6 g 117 (78.5) 14 (82.4) 103 (78.0)
6–9 g 3 (2.0) 1 (5.9) 2 (1.5)
≥9 g 7 (4.7) 1 (5.9) 6 (4.5)
Guidewire technique
Parallel wire technique 29 (19.5) 9 (52.9) 20 (15.2) 0.001
Seesaw technique 5 (3.4) 1 (5.9) 4 (3.0) 0.459
Side branch technique 2 (1.3) 0 (0) 2 (1.5) 1.000
Retrograde wire technique 4 (2.7) 0 (0) 4 (3.0) 1.000
Predilation
Size of initial predilation balloon, mm 1.78 ± 0.45 1.66 ± 0.36 1.79 ± 0.46 0.416
Stepwise predilation (from small to large balloon) 90 (60.4) 13 (76.5) 77 (58.3) 0.150
IVUS 7 (4.7) 2 (11.8) 5 (3.8) 0.183
DES
Total length, mm 54.37 ± 23.52 69.18 ± 17.92 52.46 ± 23.53 0.005
Postdilation with non-compliant balloon 24 (16.1) 4 (23.5) 20 (15.2) 0.480
Drug of DES
Paclitaxel 22 (14.8) 1 (5.9) 21 (15.9)
Sirolimus 119 (79.9) 15 (88.2) 104 (78.8) 0.590
Zotarolimus 8 (5.4) 1 (5.9) 7 (5.3)
Polymer of DES
Durable polymer 129 (86.6) 14 (82.4) 115 (87.1) 0.598
Biodegradable polymer 17 (11.4) 3 (17.6) 14 (10.6)
Mixed usage 3 (2.0) 0 (0) 3 (2.3)
Data are presented as mean ± SD or n (%). CAA indicates coronary artery aneurysm; PCI, percutaneous coronary intervention; IVUS, intravascular ultrasound; DES, drug-eluting stent.
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between the two groups. In particular, ostial occlusion (29.4% versus
9.1%, P = 0.028) was the only factor associated with CAAs after
successful CTO-PCI and DES implantation.
3.3. Procedural characteristics
The procedural characteristics including devices and techniques
were shown in Table 3. The average number of the used guidewire
was 1.9 ± 0.9 and stiffness of the guidewire tip focused from 3 to 6 g.Fig. 1. The schema of patients enrolled. This ﬁgure depicts how patients with successfully opene
chronic total occlusion; DES, drug-eluting stent; PCI, percutaneous coronary intervention; CAAThe single-wire technique was the predominant strategy used in 114
cases (76.5%) followed by the parallel wire technique in 29 cases
(19.5%). The seesaw technique (5, 3.4%), side branch technique (2,
1.3%) and retrograde wire technique (4, 2.7%) were rarely used in the
lesions including in the current study. The average DES length was
54.4±23.5mm. Themost frequently used stentswere durable polymer
stents (129, 86.6%) and sirolimus eluting stents (SES) (119, 79.9%). The
assumed inﬂuencing factors including number of guidewire, stiffness of
guidewire tip, predilation, drug andpolymer ofDES showedno signiﬁcant
differences between the two groups. However, the use of the parallelwired CTOs during the study period (2004–2010) were dispatched and selected. CTO indicates
, coronary artery aneurysm.
Fig. 2. Development of a CAA in left anterior descending artery after successful CTO-PCI and DES implantation. Panel A shows the initial lesion at August 24, 2006 and percutaneous
coronary intervention was performed. After stent implantation with paclitaxel-eluting stents 3.0 × 32 mm, 2.75 × 32 mm and 2.5 × 16 mm (B), a huge CAA was apparent on the
follow-up angiography at 34 days (C). CAA indicates coronary artery aneurysm; CTO, chronic total occlusion; PCI, percutaneous coronary intervention; DES, drug-eluting stent.
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versus 52.5 ± 23.5 mm, P = 0.005) were associated with more CAAs
after successful CTO-PCI and DES implantation.
3.4. Multiple logistic regression analysis
The multiple logistic regression analysis (Table 4) revealed that age
(OR: 0.925, CI 0.873–0.980, P = 0.008), ostial occlusion (OR: 6.715, CI
1.473–30.610, P = 0.014), the parallel wire technique (OR: 6.167, CI
1.709–22.259, P = 0.005) and DES length (OR: 1.030, CI 1.002–1.058,
P = 0.036) were the independent predictors of CAAs after successful
CTO-PCI and DES implantation.
3.5. Outcomes
During amean follow-up period of 3.9±1.6 yearswhich included at
least once angiographic follow-up in all patients, 127 patients (90.1%)
completed follow-up. The MACEs at 5-year follow-up of the CAA
group and non-CAA group were shown in Table 5. Aspirin was
prescribed after discharge for 93.8% (15/16) of patients with CAAs
and 96.8% (121/125) of patients without CAAs (P= 0.457). Clopidogrel
(at least 12-months) was deﬁnitely prescribed after discharge to all the
patients included in the current study. Themain reason for discontinuing
aspirin was gastrointestinal side-effect and bleeding. During the 5-year
follow-up, MACEs were observed in 3 patients (18.8%) in the CAA
group and 25 patients (20.0%) in the non-CAA group. There were no
cardiac deaths and MI in the CAA group. Four cardiac deaths (3.2%)
due to 3 acute MI and 1 severe heart failure were observed in the
non-CAA group. TVR was observed in 3 patients (18.8%) in the CAA
group and 22 patients (17.6%) in the non-CAA group. Overall, there
were no statistical differences of MACEs between the two groups
under the dual antiplatelet therapy (adjusted hazard ratio 0.670; 95%
CI 0.160–2.808; P = 0.584).Fig. 3. Development of CAAs in the left circumﬂex artery after successful CTO-PCI and DES im
coronary intervention was performed (A). After stent implantation with sirolimus-eluting ste
the follow-up angiography atMarch 03, 2011 (C). CAA indicates coronary artery aneurysm; CTO4. Discussion
CAAs were observed in 0.15–4.9% of the patients undergoing
coronary angiography [14]. Compared with other etiologies, the
formation of CAAs after PCI is relatively rare. The reported incidence
of CAAs is 0.3% to 6.0% for PTCA [15–18], and 0.2% to 10.5% for DES
implantation [8,19–23]. Compared with non-CTOs, our ﬁndings
showed a slightly high incidence (11.4%) of CAA detection after
successful CTO-PCI and DES implantation.
4.1. Duration of CAA detection after PCI
In previous studies, duration of CAA detection after PCI is quite vari-
able [24–27]. In one recent study by Kimwhich included 28–36 months
of angiographic follow-up [23], most of the CAAs after DES implantation
weredetected N1 year after the initial procedure. However, 76.5% (13/17)
of the CAAs in the current studywereﬁrstly detected b1 year after the 1st
successful PCI. And the shortest duration to detect a CAAwas only within
34 days. This difference of incidence and detection time resulted from
many factors such as particular institution, operator experience and
patient characteristics. But we believed that the most important factor
was the design of the multiple angiographic follow-up which would
increase the detection of late occurrence of CAA. Thus, the published
data came to the conclusion that the duration of CAA detection after PCI
was replete with uncertainty, largely because they were not formed by
a single factor, but the result of multiple ones.
4.2. Predictors of CAAs after successful CTO-PCI and DES implantation
Thedevelopment of CAAs after PCIwas reported to be a consequence
of non-procedural factors and procedural factors. Among the non-
procedural factors, age (OR: 0.925, CI 0.873–0.980, P= 0.008) and ostial
occlusion (OR: 6.715, CI 1.473–30.610, P= 0.014) were found to be theplantation. This ﬁgure depicts the initial lesion at February 07, 2009 and percutaneous
nts 3.0 × 36 mm and 2.5 × 36 mm (B), two focal CAAs (white arrow) were apparent on
, chronic total occlusion; PCI, percutaneous coronary intervention; DES, drug-eluting stent.
Fig. 4.Development of a CAA in the right coronary artery after successful CTO-PCI andDES implantation. This ﬁgure depicts the initial lesion at August 26, 2008 and percutaneous coronary
interventionwas performed (A). After stent implantationwith sirolimus-eluting stents 3.5 × 33mm(B), a CAA (white arrow)was apparent on the follow-up angiography at July 23, 2009
(C). CAA indicates coronary artery aneurysm; CTO, chronic total occlusion; PCI, percutaneous coronary intervention; DES, drug-eluting stent.
Table 4
Multivariate logistic regression analysis for independent predictors of CAAs after CTO-PCI
and DES implantation.
OR 95%CI P value
Age 0.925 0.873–0.980 0.008
Ostial occlusion 6.715 1.473–30.610 0.014
Parallel wire technique 6.167 1.709–22.259 0.005
Length of DES 1.030 1.002–1.058 0.036
CAA indicates coronary artery aneurysm; CTO, chronic total occlusion; PCI, percutaneous
coronary intervention; DES, drug-eluting stent.
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implantation in the current study. The exactmechanismof susceptibility
related to age has not yet been clariﬁed. However, the relevance of the
relationship between young age and coronary positive remodeling has
been reported in some previous studies [28,29]. Our ﬁndings shared
the similarmechanism; subsequently, larger clinical trials arewarranted
to conﬁrm thisﬁnding. Ostial lesions have been recognized as a challenge
for CTO-PCI because of difﬁculties in the placement of a guiding catheter
and poor back-up support [30–33]. To some extent, these difﬁculties can
indirectly increase the risks for vessel injurywhichmay contribute to the
CAA formation. On the other hand, among all the procedural factors, the
parallel wire technique (OR: 6.167, CI 1.709–22.259, P= 0.005) and DES
length (OR: 1.030, CI 1.002–1.058, P = 0.036) were found to be the
independent risk factors of CAAs after successful CTO-PCI and DES
implantation in the current study. During our CTO-PCI, the single-wire
technique was the predominant strategy used in 114 cases (76.5%)
followed by the parallel wire technique in 29 cases (19.5%). Generally,
when the single wire technique had failed to run through the real
lumen, the parallel wire technique logically became the primary basic
technique for CTO-PCI. Nevertheless, in spite of its contribution to the
success of CTO-PCI, the parallel wire technique seemed to increase the
risks of CAA formation in the current study. The potential cause was
that the 1st wire had already entered the subintima and created a false
lumen before the parallel wire technique was performed. Hereby, even
though the 2nd wire increased the success rate of CTO-PCI, the parallel
wire technique could not remedy and improve the preexisting damage
to the artery wall. It was consistent with the compelling evidence
provided by our study. Furthermore, DES length was one of the risk
factors for CAAs after DES implantation reported generally [23].
Our study reached the same conclusion.
4.3. Mechanism of CAAs after successful CTO-PCI and DES implantation
A new classiﬁcation had been suggested to identify the cause of
CAAs after PCI, including arterial injury, the chronic arterial response
to the DES and infection [9]. Among them, arterial injury related to
the procedure was postulated to be a more likely contributor to the
rapid development of an aneurysm after PCI than the chronic arterial
response secondary to a hyper-sensitivity reaction to the stent
polymers and drugs [8,9]. During the procedure, balloon over inﬂation
or other iatrogenic injury had already been reported to be the indepen-
dent risk factor for CAAs after DES implantation in previous observational
studies [15–17]. In view of the evidence provided by IVUS, the parallel
wire technique was obviously associated with arterial wall injury. The
mechanism lied in that the subintimal passage of the guidewire, creation
of a false lumen, and stentingwithin the false lumenmight result in injury
to the adventitial layer during CTO-PCI. Therefore, it provided evidence tous that arterial injury was the very important mechanism responsible for
CAAs after successful CTO-PCI. Otherwise, in terms of chronic arterial
response which was proved by the ﬁnding of an eosinophilic inﬁltrate
in the few cases of such poststent coronary artery aneurysms examined
histologically [34,35], long DES of CTO-PCI would aggravate this situation.
Overall, the formation of CAAs in this procedure was a combined event
including clinic characteristics, angiographic morphology, various
techniques, and DES selection, which was beyond doubt.4.4. Outcomes of CAAs after successful CTO-PCI and DES implantation
Up to now, the clinical implications of CAAs have not been deﬁnitely
determined. Hereby, it is very important and necessary for assessing
anddetecting potentially harmful complications of CAAs after successful
CTO-PCI andDES implantation. In some studies, CAAs related toDES had
been suggested predispose to stent thrombosis [23,36]. However, no
statistical difference of MACEs between the CAA group and non-CAA
group was shown in the current study. Therefore, in this study, CAAs
after successful CTO-PCI and DES implantation were not frequently
associatedwith adverse clinical events under the current dual antiplatelet
regimen. Based on these data, it could be conjectured that MACEs might
originate mainly from natural progression of coronary artery diseases,
not just only from CAAs themselves. For better understanding this
complication, further large clinical trials and follow-up studies are
needed.
In conclusion, our work represents the ﬁrst study to indicate the
independent predictors of CAAs after successful CTO-PCI and DES
implantation, which included age, ostial occlusion, the parallel wire
technique and DES length. Furthermore, we also demonstrated for
the ﬁrst time that CAAs after the index procedure would not increase
MACEs under dual antiplatelet therapy at 5-year follow-up, compared
with thenon-CAA group. These results could improve our understanding
of therapeutic intervention in cardiovascular diseases.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijchv.2014.06.004.
Table 5
Clinical outcomes at 5-year follow-up.
Patients with CAA (n = 16) Patients without CAA (n = 125) Unadjusted HR (95% CI) P value Adjusted HRa (95% CI) P value
Cardiac death 0 (0) 4 (3.2) 1.000 1.000
Myocardial infarction 0 (0) 3 (2.4) 1.000 1.000
Target vessel revascularization 3 (18.8) 22 (17.6) 0.979 (0.293–3.272) 0.973 0.804 (0.187–3.467) 0.770
MACEs 3 (18.8) 25 (20.0) 0.866 (0.261–2.868) 0.813 0.670 (0.160–2.808) 0.584
Data are presented as mean ± SD or n (%). CAA indicates coronary artery aneurysm; MACE, major adverse cardiac event, CI, conﬁdence interval; HR, hazard ratio.
a Adjusted covariates includedmale, age, history of smoking, diabetes, priormyocardial infarction, triple-vessel disease, ostial occlusion, parallelwire technique, length of drug-eluting stent.
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This studyhad two limitations. First, this studywas not a prospective
randomized trial frommultiple centers. The occurrence of MACE events
might be confounded with some factors such as different reasons for
repeat coronary angiogram. Second, the precise duration of the occlusion
was not angiographically documented, a limitation applicable to all
observational studies of CTOs.Source of funding
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